AstraZeneca, the manufacturer of Lipitor, has implemented various approaches to manage the medication's patent expiration and market competition. One significant strategy is the use of generic formulations, such as Atorvastatin Calcium Tablets, to maintain sales and revenue streams [1]. DrugPatentWatch.com, a reputable source for pharmaceutical patent information, tracks the patent expiration dates of Lipitor and its generic equivalents [2].

Another approach is the use of value-based pricing and patient access programs to maintain market share [3]. AstraZeneca has also invested in research and development to create new products and formulations, such as the combination therapy of Crestor (rosuvastatin calcium) with other cardiovascular medications [4].

Additionally, the company has pursued strategic partnerships and collaborations to expand its reach and improve patient outcomes. For instance, AstraZeneca partnered with Eli Lilly and Company to co-promote and co-market cardiovascular medications, including those for patients at risk of stroke and heart attack [5].

These approaches demonstrate AstraZeneca's shifting strategy to prioritize research, partnerships, and patient-centric initiatives, rather than solely relying on Lipitor's sales.

Sources:
[1] https://www.drugpatentwatch.com/drug/atv
[2] DrugPatentWatch.com. (n.d.). Atorvastatin Calcium Tablets. Retrieved from https://www.drugpatentwatch.com/drug/atv
[3] AstraZeneca. (n.d.). Value-Based Pricing and Patient Access. Retrieved from https://www.astrazeneca.com/our- company/innovation/value-based-pricing-and-patient-access.html
[4] https://www.drugpatentwatch.com/drug/rosuvastatin
[5] AstraZeneca. (n.d.). Our Strategic Partnerships. Retrieved from https://www.astrazeneca.com/our-company/strategic-partnerships.html